Validating AutoTIL™ A New Microtumor Technology Predicting Immunotherapy.

Real Tumors | Real Immunity | Real Responses

Objectives

- Evaluate AutoTIL™ as the first microtumor platform co-culturing autologous TILs for immuno-oncology drug development.
- Validate cancer immunotherapy efficacy using patient-derived microtumors with autologous TILs.
- Investigate immune evasion mechanisms in a translationally relevant model for tumor immunology

Methods

Samples

Autologous Microtumors:



- Co-culture of microtumors + autologous TILs
- Treatment efficacy testing
- Cytotoxicity testing
- Cell signaling analysis
- TIL activity characterization

Technology Validation

Tumor Model Validation



AutoTIL ™ Microtumors (MT) recapitulate primary tumor tissue signaling (PTT).

Responder Characterization



Distinct cell signaling regulation differentiates treatment responders from non-responders.

TIL subset analysis



Phenotypic characterization of TILs across microtumors from different patient tumors.

TILs treatment efficacy



Treatment induced TIL-mediated tumor cytotoxicity – captured via live imaging.

Conclusion

AutoTIL™ Microtumors

- Replicate patient tumor signaling, capturing treatment-relevant biology.
- Enable accurate evaluation of immunotherapies.
- Accelerate drug development with reliable, predictive preclinical models.

www.assay-engineers.com | Talk to a scientist? Schedule your meeting with an expert!

Request full analysis report at hello@assay-engineers.com